2010
Authors: Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O.
Published in: Clinical Pharmacology and Therapeutics, 2010, 87(3):294-302.
Abstract The establishment of a rationale for determining dosing regimens in pediatric patients remains a challenge in drug development. In this investigation, we explored several methodologies to support bridging studies and evaluated the best descriptor of developmental changes that can be used as a covariate for dose adjustment in children.
2006
Authors: LeProvost M, Green H, Flynn J, et al; on behalf of the PENTA 13 study group.
Published in: Pediatr Infect Dis J. 2006;25(6):533-7
Background Data on adherence to and acceptability of once daily lamivudine and abacavir are few.
Methods Twenty-four U.K. human immunodeficiency virus type-1 infected children 2-13 years of age participated in the Pediatric European Network for the Treatment of AIDS (PENTA) 13 single arm,
2005
Authors: LeProvost M, Green H, Flynn J, et al: on behalf of the PENTA 13 study group.
Published in: 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Poster MoPe9.2C03
2005
Authors: Bergshoeff A, Burger D, Verweij C, et al; on behalf of the PENTA 13 study group
Published in: Antivir Ther. 2005; 10:239-246
Background There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h) nucleoside analogues in HIV-infected children.
Methods Children aged 2-13 years receiving combination treatment containing lamivudine (3TC) (4 mg/kg) and/or abacavir (ABC) (8 mg/kg) twice daily (q12h) were included in this single-arm,
2004
Authors: Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, LeProvost M, Walker AS, Novelli V, Lyall H, Gibb DM.
Published in: 11th Conference of Retroviruses and Opportunistic Infections, San Francisco, 8-11 February 2004. Poster 934.